Hubei Biocause Pharmaceutical Cash Flow-to-Debt Ratio
Hubei Biocause Pharmaceutical cash flow-to-debt ratio. Hubei Biocause Pharmaceutical (000627) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2023, meaning its operating cash flow of CN¥276.06 Million could theoretically repay 0% of its total liabilities (CN¥272.50 Billion) in one year. Check earnings quality score of Hubei Biocause Pharmaceutical to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hubei Biocause Pharmaceutical (2001–2023)
Cash flow-to-debt ratio of Hubei Biocause Pharmaceutical from 2001 to 2023. Historical debt coverage capacity for Hubei Biocause Pharmaceutical across 18 annual periods. Check how aggressively does Hubei Biocause Pharmaceutical reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Hubei Biocause Pharmaceutical Cash Flow-to-Debt Ratio by Year (2001–2023)
Hubei Biocause Pharmaceutical cash flow-to-debt ratio by year from 2001 to 2023. Year-by-year debt coverage analysis for Hubei Biocause Pharmaceutical. For the full cash flow conversion analysis, see 000627 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | 0.04x | CN¥9.53 Billion | CN¥268.30 Billion | ▲ +20.0% |
| 2022 | 0.03x | CN¥7.52 Billion | CN¥254.00 Billion | ▲ +60.8% |
| 2021 | 0.02x | CN¥4.17 Billion | CN¥226.43 Billion | ▼ -82.4% |
| 2020 | 0.10x | CN¥21.42 Billion | CN¥204.81 Billion | ▼ -37.5% |
| 2019 | 0.17x | CN¥28.60 Billion | CN¥170.92 Billion | ▲ +70.0% |
| 2018 | 0.10x | CN¥14.98 Billion | CN¥152.24 Billion | ▲ +2492.8% |
| 2017 | 0.00x | CN¥431.58 Million | CN¥113.71 Billion | ▲ +115.8% |
| 2016 | -0.02x | CN¥-2.34 Billion | CN¥97.48 Billion | ▲ +67.8% |
| 2015 | -0.07x | CN¥-46.73 Million | CN¥625.50 Million | ▼ -141.3% |
| 2013 | 0.18x | CN¥130.53 Million | CN¥720.71 Million | ▲ +1.8% |
| 2012 | 0.18x | CN¥93.79 Million | CN¥527.37 Million | ▲ +24.7% |
| 2011 | 0.14x | CN¥66.95 Million | CN¥469.47 Million | ▼ -76.2% |
| 2010 | 0.60x | CN¥224.58 Million | CN¥374.25 Million | ▲ +132.1% |
| 2007 | 0.26x | CN¥118.56 Million | CN¥458.52 Million | ▼ -10.5% |
| 2006 | 0.29x | CN¥128.19 Million | CN¥443.66 Million | ▲ +111.8% |
| 2005 | 0.14x | CN¥48.66 Million | CN¥356.70 Million | ▼ -13.0% |
| 2004 | 0.16x | CN¥56.07 Million | CN¥357.41 Million | ▼ -4.9% |
| 2001 | 0.16x | CN¥37.30 Million | CN¥226.09 Million | — |